Maintenance therapy of Zanubrutinib after autologous hematopoietic stem cell transplantation for primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035939

Enrollment

Unknown

Registered

2020-08-20

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary CNS Lymphoma

Interventions

Case series:Zanubrutinib

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old male or female; 2. non Hodgkin's lymphoma was diagnosed by histopathology and immunohistochemical staining, and no systemic LYMPHOPOIETIC tissue or other system involvement was found after strict physical examination and auxiliary examination, which was definitely diagnosed as primary central nervous system lymphoma; 3. complete remission was assessed by PET-CT after autologous hematopoietic stem cell transplantation; 4. The subjects read and fully understood the patient's instructions and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Combined with other malignant tumors; 2) Severe heart failure, liver dysfunction or renal insufficiency; 3) Severe arrhythmia; 4) Pregnancy or lactation of women; 5) Recent participants in other clinical trials; 6) Other major diseases or mental disorders.

Design outcomes

Primary

Measure	Time frame
PFS;relapse rate;	—

Secondary

Measure	Time frame
OS;Incidence of adverse reactions;	—

Contacts

Public ContactYan Ma

Huashan Hospital, Fudan University

mayan1024@126.com+86 021-66895019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026